Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cellsPartow Kebriaei, Laurence J.N. Cooper|Journal of Clinical Investigation|2016Cited by 499
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trialDavid Marín, Katayoun Rezvani, Merve Dede et al.|Nature Medicine|2024Cited by 452
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop M. Kantarjian, Susan O’Brien, Deborah A. Thomas et al.|The Lancet Oncology|2012Cited by 411
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaHagop M. Kantarjian, Susan O’Brien, Deborah A. Thomas et al.|Cancer|2013Cited by 302
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapyKris M. Mahadeo, Sajad Khazal, Hisham Abdel‐Azim et al.|Nature Reviews Clinical Oncology|2018Cited by 236